Connect with us

News

Danish startup’s tech-enabled jewellery to tackle sexual harassment

Published

on

With jewellery that doubles as a discreet safety device, Danish startup All U Me is combining social impact with innovation to address the significant impact of sexual harassment on women’s health and wellbeing.

One in three women has experienced physical or sexual violence, and around half have experienced sexual harassment since the age of 15. The misconception that these incidents always occur late at night and in dark alleyways overlooks the reality of these experiences, which for many women are a part of everyday life.

The Government Equalities Office reports that almost 72 per cent of the UK population has experienced sexual harassment at work in their lifetime. Research shows that 56 per cent of women have experienced harassment in gyms, while 60 per cent of women had been harassed while running, and 11 per cent stopped running altogether as a result.

“It’s the everyday experiences that are the problem,” Dorte Caroline Knudsen (pictured above), founder of Danish startup All U Me tells Femtech World. 

“It’s not just walking down a dark street in the middle of the night, it’s the everyday, in the supermarket, on the bus, where you experience feeling unsafe or your boundaries not being respected. It’s the mental load that women are expected to carry, almost without talking about it, to get home safely. I can get home safe; I’m not the problem.”

After 14 years as head of products at a Danish software company, at the age of 47, Knudsen felt called to channel her skills into more purposeful entrepreneurship. Inspired by the UN’s Sustainable Development Goals and anger at the global prevalence of gender-based violence, she began looking into what solutions were currently being developed to address it.

“It was sad to see that none of the solutions said anything about prevention,” she says. “All the focus was on normalising what is going on and putting the responsibility on women.”

In response, Knudsen has created a solution that aims to empower women, while also shifting “safety” from an individual to a collective responsibility. 

“The beauty of feeling free”

All U Me has designed a range of jewellery featuring delicate gold and silver chains and ocean-inspired charms, which double up as an alarm system to enable them to call for help when they feel unsafe. 

“Tech is wonderful, but it can do more when it’s put into something beautiful, which is very rarely seen in the tech space,” says Knusden.

“Most of the existing solutions were one-size-fits-all, but women don’t work like that. We want to wear something that makes us feel beautiful.”

As well as being beautiful to look at, the jewellery is practical. Fully waterproof and with a battery life lasting up to four years, it is designed to be worn all the time, making it “probably the first real wearable”, according to Knusden. 

Each item has a discreet button, linked via Bluetooth and GPS to an app connecting the wearer to nearby bystanders. This may be friends or family who have downloaded the app to their phone specifically for this purpose, or other All U Me users in the local area. 

If a woman finds herself in an uncomfortable or unsafe situation, three firm pushes of the button notify up to 20 nearby bystanders or ‘backups’ with her location, alerting them to the incident so that they can intervene. 

The app trains all users in the 5D bystander intervention method – distract, delegate, delay, direct, document – in as little as three minutes, so they can choose the approach that feels right at the time. 

This is designed to break down some of the barriers that may prevent people from stepping in, such as not noticing, not being sure whether help is wanted, or not knowing what to do, Knudsen explains. 

“The feedback we get from the workshops we do is that people like to have a framework. Empowering bystanders, by telling them ‘this is what you need to do’, and ‘this is when you need to do it’, makes people a little bit more inclined to help,” she says.

“It’s no more genius than the technology that already exists, and there are times when it might not work, but that’s why the feeling of security is so important, because that’s the everyday benefit of this.”

According to All.u.me’s focus groups, 98.8 per cent of people being trained in these methods feel there’s at least one thing they can do the next time they witness harassment, while 76 per cent who saw harassment after attending the training reported that they intervened.

“The jewellery is just one element,” Knudsen continues.

“It’s actually much more about the feeling of safety and belonging to a community that I hear our users appreciate every day, and the dialogue around it. Maybe it’s telling your loved ones why you want this jewellery, or maybe it’s somebody on the bus, or the bus driver, the bartender, or the guy at the fitness center who has the app. It’s not a guarantee, but that’s where the social responsibility kicks in, and of course, our most important job is to make sure that people have the app.”

Reframing femtech

Safety and sexual harassment can be overlooked in the femtech sector. Both the World Health Organization and the US Centers for Disease Control classify sexual violence as a major public-health issue, and evidence shows that these experiences can not only have a significant impact on mental health but can also lead to physical symptoms and an increased risk of developing chronic conditions, contributing to long-term health disparities.

One recent study found that women who had experienced being stalked and/or obtained a restraining order had a 41 per cent and 70 per cent higher risk of developing cardiovascular disease, respectively. Other research has shown that women with a history of violence are around twice as likely to develop chronic pain conditons and are over-represented among women with conditions such as chronic pelvic pain, IBS, and migraine

In many ways, All U Me expands the understanding of femtech, centering safety as a foundation for health and equality. But Knusden is wary of being labelled as a ‘femtech’ company.

“The fact that safety is not seen as femtech is quite weird, actually, when statistically so many of us will experience harassment,” she says.

“But I also want to acknowledge that there are so many people who can benefit from this. It’s not just about gender equality, it’s for anybody who may feel unsafe in society.”

Not a jewellery brand, but a tech enabler 

The more people who have the app, the more effective the tool is. While women can create their own networks from anywhere by asking friends and family to download the app, it works most effectively in more populated urban areas where more users are likely to be within a 1 km range.

Since launching in June, All U Me now has 2,000 active subscribers in Copenhagen. There are plans to expand into Sweden, Germany, and the UK, but partnerships with existing jewellery brands – to integrate its safety devices into their existing designs – will be crucial for helping this technology reach more women. 

“There are so many jewelry brands in the world, I don’t want to be another one,” says Knusden. 

“We want to be a technology enabler. Our vision is to empower and inspire everyone – people, brands, organisations – to stand against harassment, whether they do it by downloading the app, or partnering with us to make the jewellery. This is how we will scale through these partnerships.”

She has big ambitions, believing All U Me could be the “first social impact unicorn”, combining scalable tech, commercial sustainability, and philanthropy. 

“I have global ambitions with this, but I also have philanthropical ambitions, in the sense that I believe that every young girl and woman should be able to feel safe and be who they are, Knusden adds. 

Sharing her experience of using All U Me, one woman described her sense of safety as going from a “two to a four out of five”. 

“Her feeling of safety doubled,” Knusden emphasises. “It’s not a 100 per cent guarantee, but it meant that she stopped carrying her keys between her fingers. If we can make people feel safer, and if we can make it easier for bystanders to act, then we can change the world.”

 

Fertility

Scottish gov to consider IVF for single women

Published

on

The Scottish government has launched a national review into whether NHS IVF access should be extended to single women.

The review will also consider whether wider access should be offered to couples who have children from previous relationships.

Health secretary Angela Constance said: “Access to NHS IVF treatment should be fair, timely and reflect the way people’s lives and families look today.”

Most single women are not currently eligible for NHS IVF treatment in Scotland.

Campaigners have welcomed the review.

Katie Rollings of Fertility Action said: “It’s an essential and long-awaited decision that will impact a huge number of people who are struggling to grow their families.

She said there is “no evidence” that having two parents rather than one determines whether a child will thrive.

She added: “What matters is whether a child is loved, safe, supported and has stable, positive relationships around them.”

Figures from the Human Fertilisation and Embryology Authority show Scotland is the only UK nation where NHS-funded IVF cycles outnumber privately funded cycles.

In 2024, more than 6,000 cycles of fertility treatment were carried out among more than 4,000 patients in Scotland. Both figures were slightly lower than the record highs recorded in 2022.

The past 20 years have also seen a rise in the number of same-sex female couples and single women receiving fertility treatment.

In 2024, 625 IVF cycles were carried out for women in same-sex couples in Scotland, with more than one third funded by the NHS.

There were 330 cycles involving single women, of which 50 were NHS-funded.

In England, single women can access IVF through the NHS, although eligibility varies according to the local health trust’s policy.

Current Scottish rules state that couples are eligible if they have been living in a stable relationship for two years and neither partner has been sterilised.

Couples where one partner already has a child can be eligible, but those where both partners have children from previous relationships are not.

Eligibility rules also require a body mass index above 18.5 and below 30, and state that couples must not smoke, drink alcohol or take drugs during treatment. The mother must be under 42.

The Scottish government said the review would also examine consistency of access to fertility preservation, including during cancer treatment, as well as reducing waiting times for donor eggs and sperm.

Same-sex female couples already have access to NHS IVF, but they can face long waits for donor eggs or sperm, as can heterosexual couples who require donor treatment.

The National Fertility Group will lead the review and make “costed, demand-modelled recommendations”, which are due to be published by early summer 2027.

The group will include fertility experts from Scotland’s four NHS-assisted conception units in Glasgow, Edinburgh, Aberdeen and Dundee.

Prof Sarah Martins Da Silva, an NHS consultant and chair of fertility medicine at Dundee University, said there were questions to be answered in a resource-stretched NHS.

“As a fertility specialist I’m never going to be disappointed if the criteria is widened,” she said.

“But with single people, as an NHS clinician looking at the competing demands we have, I’d ask the question about whether being single is a health condition that needs to be funded.”

Da Silva said NHS waiting lists were full of couples who require donated eggs or sperm because of medical conditions including cancer and could face longer waits.

“It’s slightly a disservice to them,” she said.

“There would need to be a real investment and resource without making everybody wait an extraordinary long time.

“With the current financial environment we work in, if you’re talking about new money, where would that come from?”

She said she would welcome changes that encouraged more people to donate eggs or sperm and questioned whether arguments about children needing two parents were necessarily relevant to the debate.

“On the one hand bringing up a child is quite an expensive process, and if you don’t have that support, it can be very difficult.

“But on the other hand, many people start off as a couple and divorce.”

Da Silva also welcomed plans for the review to consider eligibility for couples who already have children, describing the move as “fantastic”.

Continue Reading

Diagnosis

FDA approves AstraZeneca breast cancer drug

Published

on

The FDA has granted accelerated approval to AstraZeneca drug Etcamah for certain adults with advanced breast cancer carrying an ESR1 mutation.

Etcamah, also known as camizestrant, was approved in combination with a CDK4/6 inhibitor, either abemaciclib, palbociclib or ribociclib.

The treatment is for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer when an estrogen receptor-1 (ESR1) mutation is detected during aromatase inhibitor and CDK4/6 inhibitor therapy using an FDA-authorised test.

ESR1 mutations are acquired resistance mutations that tumours may develop during treatment with aromatase inhibitors, a type of endocrine therapy commonly used as a front-line treatment for locally advanced or metastatic breast cancer.

Fewer than 5 per cent of patients have the mutation when HR-positive metastatic breast cancer is diagnosed, according to the FDA. After disease progression on an aromatase inhibitor, nearly 40 per cent have the mutation.

Acting FDA commissioner Kyle Diamantas said: “Women living with metastatic breast cancer face an uphill battle as their tumors continuously evolve to escape treatment.

“We owe them every weapon in our arsenal.

“Today’s approval delivers a win to these patients by granting them a targeted therapy designed specifically to overcome resistance, giving them more time before their disease progresses.”

The accelerated approval programme allows earlier approval of drugs that treat serious conditions and fill an unmet medical need based on surrogate or intermediate endpoints.

For Etcamah, approval was based on how long patients lived without their disease worsening, measured from when the resistance mutation was first detected in their blood.

The FDA said it has not yet been confirmed whether intervening when the mutation is detected, rather than waiting until disease progression is confirmed, results in a clinically meaningful benefit. Confirmatory studies are therefore required to verify and describe clinical benefit.

Angelo de Claro, director of the FDA’s Oncology Center of Excellence, said: “I commend both the FDA and the sponsor for their commitment to advancing cancer care and securing this accelerated approval.

“This marks the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA (ctDNA) before imaging tests show that the disease is progressing.

“But additional evidence is needed to confirm clinical benefit.”

Circulating tumour DNA, or ctDNA, consists of small pieces of tumour DNA released into the blood and can allow earlier molecular detection of resistance mutations.

The FDA also authorised the Guardant360 CDx assay as a companion diagnostic to identify patients with breast cancer who have ESR1 mutations for treatment with camizestrant.

Efficacy was assessed in a clinical trial comparing a switch to Etcamah plus a CDK4/6 inhibitor with continued treatment using an aromatase inhibitor plus a CDK4/6 inhibitor.

Estimated median progression-free survival was 16 months in the Etcamah group, compared with 9.2 months in the aromatase inhibitor group.

Etcamah’s prescribing information includes a boxed warning about the risk of irregular heart rhythm when taken with certain other medicines. It also includes warnings about an abnormally slow heart rate and potential harm to an unborn baby.

The FDA convened its Oncologic Drugs Advisory Committee for the application on 30 April 2026.

Continue Reading

Entrepreneur

Last chance to save on Women’s Health Week and Women’s Sport Summit: Early Bird pricing ends 11 September

Published

on

Early bird pricing for W Group’s two flagship October summits – Women’s Health Week Europe 2026 and Women’s Sport Summit Europe 2026 – closes on 11 September.

Both events take place at Emirates Stadium, London, bringing together founders, investors, corporates, and industry leaders shaping the future of women’s health and sport.

Women’s Health Week Europe 2026

7-8 October | Emirates Stadium, London

This year’s edition will be Women’s Health Week Europe biggest one yet: with 700+ attendees, 80+ speakers, and 20+ sponsors, it will also feature two stages – a Global Stage covering market trends and policy, and a Scale Stage focused on company-level growth and commercialisation. WHW takes place across two days of content, business matchmaking, and dealmaking.

Agenda highlights include:

  • Where Capital Flows: Funding Trends in Women’s Health – with Merete Clausen (EIF), Ekaterina Gianelli (Calm/Storm), Henriette Hessen (Verdane), Jemma Day (British Business Bank), Ravit Warsha Dor (Telus Global Ventures), Tim Davis (LSEG)
  • Six Feet Under-funded: Surviving the Valley of Death in Women’s Health – with Patric Stenberg (Gesynta Pharma), Valentina Milanova (Daye), Amber Vodegel (28x)
  • The Women’s Health Label – Gift or Curse? · Live Debate – with Juan Camilo Arjona Ferreira (organon), Marissa Fayer (DeepLook Medical), Christian Lautner (Heal Capital), Annie Theriault (CBIV), Ida Tin (Clue)
  • Passport to Scale: Taking Your Women’s Health Business Global – with Vanessa Carpenter (Femtech Across Borders), Annie Theriault (CBIV), Victorine Lançon (Daya Ventures), Dr Mridula Pore (Peppy)

Early bird pricing (ends 11 September):

Ticket typeEarly birdStandard
Startups, Scaleups, Investors, Non-Profits, Government£599 + VAT£699 + VAT
Corporates, Payors & Providers£1,799 + VAT£1,999 + VAT
Service Providers & Consultants£3,299 + VAT£3,499 + VAT

Register for Women’s Health Week Europe | See the full agenda for WHW

Women’s Sport Summit Europe 2026

6 October | Emirates Stadium, London

The first-ever Women’s Sport Summit expands W Group’s expertise in connecting key decision-makers to the sports industry.

WSS brings together rights holders, brands, investors, athletes, and media to accelerate commercial growth across the sector.

Agenda highlights include:

  • From capital to crowd: the women’s sport cycle at scale – with Omar Shaikh (Arsenal FC), Nicole McWilliams (Google), Kerstin Lutz (Mercury13), Jo Currie (BBC Sport)
  • Women’s sport through the investor lens: what gets funded – and why – Hugo Sever (APEX Capital)
  • Rethinking ROI: what are we measuring that doesn’t actually matter? – Fi Watherston (Metro Bank), Silvia Keiser (Billie Jean King Cup), Gabriel Akin-Odujobi (Crux Football), Tammy Parlour (WST)
  • Beyond the 90 minutes: matchday as a commercial product, not just a fixture – Maggie Murphy (Aston Villa Women FC), Sam Feasey (Diageo/Guinness), Molly Miller (OneFootball), Megan Feringa (The Athletic/The New York Times)

Early bird pricing (ends 11 September):

Ticket typeEarly birdStandard
General Pass£299 + VAT£399 + VAT
Service Providers & Consultants£1,799 + VAT£1,999 + VAT

Register for Women’s Sport Summit Europe | See the full agenda for WSS

Attending both events?

For group tickets or to attend both summits this October, contact Callum, W Group’s Client Success Lead, at [email protected].

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.